Loading news...
Cornerstone Investment Partners LLC purchased a new stake in Thermo Fisher Scientific Inc. (NYSE: TMO) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 85,342 shares of the medical research company's stock, valued at approximately $41,393,000. A number of other institutional
Caprock Group LLC acquired a new stake in Thermo Fisher Scientific Inc. (NYSE: TMO) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 8,500 shares of the medical research company's stock, valued at approximately $4,188,000. Other hedge funds and other institutional investors have
Atria Investments Inc trimmed its stake in Thermo Fisher Scientific Inc. (NYSE: TMO) by 31.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 33,246 shares of the medical research company's stock after selling 15,333 shares during the
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced a strategic data collaboration with Datavant, the data collaboration platform trusted for healthcare, to make it easier for pharmaceutical and biotech companies to connect real-world data with clinical research—helping them generate stronger evidence, faster. Thermo Fisher's PPD™ clinical research business and Datavant will enable secure connection and analysis of real-world data (RWD.
ABC Arbitrage SA acquired a new position in Thermo Fisher Scientific Inc. (NYSE: TMO) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 2,701 shares of the medical research company's stock, valued at approximately $1,310,000. A number of
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of $3.8 billion aggregate principal amount (the “Offering”) of the following notes: $1.0 billion aggregate principal amount of its 4.215% senior notes due 2031 (the “2031 notes”) at the issue price of 100.000% of their principal amount; $750 million aggregate principal amount of its 4.550% senior notes due 2033 (the “2033 notes”) at the issue price of 99.78.
Smartleaf Asset Management LLC increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 33.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,119 shares of the medical research company's stock after purchasing an additional 1,284 shares during
Nuance Investments LLC trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 39.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,997 shares of the medical research company's stock after selling 34,898 shares
Shares of Thermo Fisher Scientific Inc. (NYSE: TMO - Get Free Report) have been given an average rating of "Moderate Buy" by the twenty-two brokerages that are currently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation, eighteen have assigned a buy recommendation and one has assigned a strong
Insightful Moves in the Fourth Quarter of 2025 Manning and Napier Group, LLC (Trades, Portfolio) recently submitted its 13F filing for the fourth quarter of 2025
Thermo Fisher delivered strong Q1 results, beating expectations with revenue of $12.21B (+7% YoY) and EPS of $6.57 (+8%). I reaffirm my strong buy rating on TMO, setting a target price of $668 per share, citing resilient margins and competitive positioning. TMO's 2026 guidance calls for $46.3B-$47.2B revenue (+4-6%) and EPS of $24.22-$24.80 (+6-8%), with organic growth of 4%.
Q4 Revenue: $12.21 billion, up 7% year-over-year.Q4 Adjusted Operating Income: $2.88 billion, up 6% year-over-year.Q4 Adjusted Operating Margin: 23.6%.Q4 Adjus
Thermo Fisher Scientific Inc. (TMO) Q4 2025 Earnings Call Transcript
Thermo Fisher Scientific Inc. (NYSE: TMO) on Thursday reported fourth-quarter 2025 adjusted earnings of $6.57 per share, beating the street view of $6.45.
Thermo Fisher Scientific Inc (NYSE:TMO, XETRA:TN8) delivered a fourth quarter earnings beat, but its shares moved lower as investors focused on margin pressures and cautious earnings guidance for 2026. The life sciences tools and diagnostics company guided 2026 revenue to a range of $46.3 billion to $47.2 billion, implying 4% to 6% growth and organic growth of 3% to 4%, broadly in line with consensus expectations and indicating continued modest demand across biopharma and life sciences end markets.
Although the revenue and EPS for Thermo Fisher (TMO) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
TMO beats Q4 EPS and revenue estimates, posts 7.1% sales growth, and sees shares rise after results despite margin pressure.
Thermo Fisher Scientific (TMO) came out with quarterly earnings of $6.57 per share, beating the Zacks Consensus Estimate of $6.43 per share. This compares to earnings of $6.1 per share a year ago.
Stock News Amazon trims 16,000 roles: Amazon (AMZN) will eliminate about 16,000 positions as part of ongoing restructuring, offering most U.S. staff 90 days for
Thermo Fisher Scientific on Thursday beat Wall Street estimates for fourth-quarter profit and revenue on strong demand for its tools and services used in drug development by pharmaceutical clients.